Severe Community- Acquired Pneumonia

  • Paul Ellis Marik


In the United States, community-acquired pneumonia (CAP) in adults results in approximately 600,000 hospital admissions annually and ranks as the sixth leading cause of death. Of those patients with CAP hospitalized, between 18% and 36% require treatment in an ICU. The mortality of these patients is about 35%. While approximately 20% of patients admitted to the ICU with CAP are in septic shock, the mortality of these patients may be as high as 60%.


Pleural Fluid Bronchiolitis Obliterans Pneumococcal Pneumonia Chest Tube Drainage Eosinophilic Pneumonia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Selected References

  1. 1.
    Bartlett JG, Breiman BR, Mandell LA, File TM. Community-acquired pneumonia in adults: Guidelines for management. Clin Infect Dis. 1998;26: 811–838.PubMedCrossRefGoogle Scholar
  2. 2.
    Davies RJ, Traill ZC, Gleeson FV. Randomised controlled trial of intrapleural streptokinase in community acquired pleural infection. Thorax. 1997;52:416–421.PubMedCrossRefGoogle Scholar
  3. 3.
    Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity and initial antimicrobial therapy. Am Rev Respir Dis. 1993;148:1418–1426.Google Scholar
  4. 4.
    Harwell JI, Brown RB. The drug-resistant pneumococcus. Clinical relevance, therapy and prevention. Chest. 2000;117:530–541.PubMedCrossRefGoogle Scholar
  5. 5.
    Henke CA, Leatherman JW. Intrapleurally administered streptokinase in the treatment of acute loculated nonpurulent parapneumonic effusions. Am Rev Respir Dis. 1992;145:680–684.PubMedGoogle Scholar
  6. 6.
    Leroy O, Santre C, Beuscart C, et al. A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. Intensive Care Med. 1995;21:24–31.PubMedCrossRefGoogle Scholar
  7. 7.
    Leroy O, Vandenbussche C, Coffinier C, et al. Community-acquired aspiration pneumonia in intensive care units. Epidemiological and prognosis data. Am J Respir Crit Care Med. 1997;156:1922–1929.PubMedGoogle Scholar
  8. 8.
    Moine P, Vercken JB, Chevret S, Gajdos P. Severe community-acquired pneumococcal pneumonia. The French Study Group of Community- Acquired Pneumonia in ICU. Scand J Infect Dis. 1995;27:201–206.PubMedCrossRefGoogle Scholar
  9. 9.
    Niederman MS. Severe community-acquired pneumonia: what do we need to know to effectively manage patients? Intensive Care Med. 1996;22: 1285–1287.PubMedCrossRefGoogle Scholar
  10. 10.
    Rudin ML, Michael JR, Huxley EJ. Community-acquired acinetobacter pneumonia. Am J Med. 1979;67:39–43.PubMedCrossRefGoogle Scholar
  11. 11.
    Thornsberry C, Hickey ML, Kahn J, Mauritz Y, Sahm DE Surveillance of antimicrobial resistance among respiratory tract pathogens in the United States, 1997 to 1998. Drugs. 1999;58(suppl 2):361–363.CrossRefGoogle Scholar
  12. 12.
    Torres A, Serra-Bataille J, Ferrer A et al. Severe community-acquired pneumonia epidemiology and prognostic factors. Am Rev Respir Dis. 1991;144: 312–318.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York, Inc. 2001

Authors and Affiliations

  • Paul Ellis Marik
    • 1
  1. 1.Critical Care MedicineMercy Hospital of PittsburghPittsburghUSA

Personalised recommendations